The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer

Title:The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer

Volume: 24

Author(s): Shiqi Dong, Chao Chen, Chang Di, Shufan Wang, Quan Dong, Wenxin Lin and Duo Liu*

Affiliation:

• Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, 150086, China

Keywords: ROS, NADPH oxidase 2, Cancer Drug Development, Drug Resistance, Cancer, Tumor

Abstract: NADPH oxidase, as a major source of intracellular reactive oxygen species (ROS), assumes an important role in the immune response and oxidative stress response of the body. NADPH 9 oxidase 2 (NOX2) is the first and most representative member of the NADPH oxidase family, and its effects on the development of tumor cells are gaining more and more attention. Our previous study suggested that NCF4 polymorphism in p40phox, a key subunit of NOX2, affected the outcome of diffuse large B-cell lymphoma patients treated with rituximab. It hypothesized that NOX2-mediated ROS could enhance the cytotoxic effects of some anti-tumor drugs in favor of patients with tumors. Several reviews have summarized the role of NOX2 and its congeners-mediated ROS in anti-tumor therapy, but few studies focused on the relationship between the expression of NOX2 and anti-tumor drug resistance. In this article, we systematically introduced the NOX family, represented by NOX2, and a classification of the latest inhibitors and agonists of NOX2. It will help researchers to have a more rational and objective understanding of the dual role of NOX2 in tumor drug resistance and is expected to provide new ideas for oncology treatment and overcoming drug resistance in cancer.

Cite this article as:

Dong Shiqi, Chen Chao, Di Chang, Wang Shufan, Dong Quan, Lin Wenxin and Liu Duo*, The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer, Current Cancer Drug Targets 2024; 24 () . https://dx.doi.org/10.2174/0115680096277328240110062433